Crassula Pharmaceuticals Launches Gasflum, Esomeprazole 40mg Coated Tablet, in Honduras
Tegucigalpa, Honduras – Crassula Honduras, a premier pharmaceutical manufacturer, proudly announces the launch of Gasflum, an esomeprazole 40mg coated tablet, enhancing its portfolio of high-quality healthcare solutions in Honduras. Designed for effective management of acid reflux and related conditions, Gasflum offers a significant advancement in treating gastroesophageal reflux disease (GERD), peptic ulcers, and excessive stomach acid production.
Esomeprazole, the active component of Gasflum, is a proton pump inhibitor (PPI) that effectively reduces stomach acid. The coated tablet formulation ensures ease of use and adherence, with a convenient once-daily dosing.
“Crassula Honduras is committed to improving healthcare outcomes with accessible and innovative treatments. Gasflum represents our dedication to providing effective solutions for managing gastrointestinal conditions,” said Dr. Roopesh Gupta, CEO at Crassula Pharmaceuticals. “We aim to enhance the quality of life for patients in Honduras, making advanced care readily available.”
For more details on Gasflum and other products, visit www.crassulapharma.com or contact sales@crassulapharma.com
About Crassula Honduras
Crassula Honduras specializes in high-quality healthcare products, focusing on innovation, quality, and patient safety to improve health and well-being in Honduras and beyond. Our diverse product range addresses various therapeutic areas, meeting the healthcare needs of our community.
2 Responses
All the best
Congratulations.